Pharmacological Profile of a Novel Phosphodiesterase 4 Inhibitor, 4-(8-Benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic Acid (NVP-ABE171), a 1,7-Naphthyridine Derivative, with Anti-Inflammatory Activities
Authors:
- Alexandre TrifilieffAlexandre Trifilieff
- Daniel WyssDWDaniel Wyss
- Christoph WalkerCWChristoph Walker
- Lazzaro MazzoniLMLazzaro Mazzoni
- Rene HerspergerRHRene Hersperger
- 1 April 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 301 (1) , 241-248
Abstract
We investigated the pharmacology of a new class of phosphodiesterase 4 (PDE4) inhibitor, 6,8-disubstituted 1,7-naphthyridines, by using 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171) as a representative compound and compared its potency with the most advanced PDE4 inhibitor, undergoing clinical trials, Ariflo [cis-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl-r-1-cyclohexanecarboxylic acid)]. NVP-ABE171 inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D with respective IC50 values of 602, 34, 1230, and 1.5 nM. Ariflo was about 40 times less potent. In human cells, NVP-ABE171 inhibited the eosinophil and neutrophil oxidative burst, the release of cytokines by T cells, and the tumor necrosis factor-α release from monocytes, in the nanomolar range. Ariflo presented a similar inhibition profile but was 7 to 50 times less potent. In BALB/c mice challenged with lipopolysaccharide, NVP-ABE171 inhibited the airway neutrophil influx and activation with an ED50 in the range of 3 mg/kg. Ariflo was inactive up to a dose of 10 mg/kg. In ovalbumin sensitized Brown Norway rats, NVP-ABE171 inhibited the lipopolysaccharide-induced airway neutrophil influx and activation (ED50 of 0.2 mg/kg) and the ovalbumin-induced airway eosinophil influx and activation (ED50 of 0.1 mg/kg). Ariflo was about 100 times less potent in both models. In the ovalbumin model, NVP-ABE171 had a duration of action of more than 24 h. NVP-ABE171 is a novel PDE4 inhibitor that shows activity both in vitro on human inflammatory cells and in vivo in animal models of lung inflammation. This compound class may have potential for the treatment of airway inflammatory conditions such as asthma and chronic obstructive pulmonary diseases.Keywords
This publication has 24 references indexed in Scilit:
- Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway ratsBritish Journal of Pharmacology, 2001
- Comparison of PDE 4 Inhibitors, Rolipram and SB 207499 (ArifloTM, in a Rat Model of Pulmonary NeutrophiliaPulmonary Pharmacology & Therapeutics, 2001
- ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to ClinicPulmonary Pharmacology & Therapeutics, 1999
- Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide‐induced inflammation in mouse lungBritish Journal of Pharmacology, 1998
- RPR 106541, a novel, airways‐selective glucocorticoid: effects against antigen‐induced CD4+T lymphocyte accumulation and cytokine gene expression in the Brown Norway rat lungBritish Journal of Pharmacology, 1997
- In vitrodifferentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor‐αrelease by PDE inhibitorsBritish Journal of Pharmacology, 1997
- Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?Trends in Pharmacological Sciences, 1997
- Effect of cyclo‐oxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide‐induced neutrophil infiltration in mouse lungBritish Journal of Pharmacology, 1996
- Molecular cloning and functional expression in yeast of a human cAMP‐specific phosphodiesterase subtype (PDE IV‐C)FEBS Letters, 1995
- Mucosal Inflammation in AsthmaAmerican Review of Respiratory Disease, 1990